← Back to headlines
UBS Initiates Coverage on Jasper Therapeutics (JSPR) at Neutral
UBS has begun its coverage of Jasper Therapeutics (JSPR) with a 'Neutral' rating, despite acknowledging progress in the company's drug Briquilimab.
29 Mar, 20:50 — 29 Mar, 20:50
Sources
Showing 1 of 1 sources
Related Stories
CK Life Sciences Plans Fast Track for Cancer Vaccines in China
8m ago
South Korea's Bio-Health Exports Reach Record $27.9 Billion
9m ago
Reader Expresses Frustration Over Access to Personal Birth Information in Finland
9m ago
Concerns Raised Over Potential Solvency of US Medicare Hospital Insurance Fund
21m ago